Kornimate/medical-research-clean huggingface dataset:
intravenous exenatide (byetta) during surgery

Conditions: Euglycemia; Hypoglycemia; Hyperglycemia

Summary: the purpose of this project is to study if intravenous exenatide is effective at maintaining normal blood glucose levels and preventing low blood glucose levels during surgery.

this is a single-center, block randomized, double-blind, placebo-controlled, dose-ranging study. subjects will be randomized in equal proportions to one of three treatment arms: placebo of normal saline solution, 0.27 ng/kg/min (0.066 pmol/kg/min) iv exenatide, and 0.41 ng/kg/min (0.099 pmol/kg/min) iv exenatide. we will use a block number of 30 (please see power analysis) so that balance between each of the three groups will be maintained over the enrollment period. we will stratify the randomization scheme to ensure balance of diabetics and non-diabetics within the groups.

Eligibility criteria:
inclusion criteria: * age (\>18 years) * weight of \> 50 kg and \< 150 kg * ability to provide informed consent * elective surgery including: * cardiac surgery to include elective cabg with or without single or multivalve repair or replacement and/or single or multivalve repair/replacement requiring cpb and sternotomy (to include subjects who are undergoing first time or redo cardiac surgery) * abdominal aortic aneurysm repair * carotid endarterectomy * esophagectomy * cystectomy * nephrectomy * if female, subject must be non-lactating, and, if of childbearing potential, must have a negative urine pregnancy test within 24 hours prior to receiving study drug exclusion criteria: * age (\<18 years) * inability to provide informed consent * history or risk of pancreatitis (e.g. ethanol abuse, gall stones) * receipt of an investigational drug or device with 30 days prior to surgery * use of any concomitant medication listed above on the day of surgery * known allergy to exenatide, fentanyl, midazolam, isoflurane, propofol, heparin or neuromuscular blockers * known substance abuse * surgical procedure other than: cardiac surgery to include elective cabg with or without single or multivalve repair or replacement and/or single or multivalve repair/ replacement requiring cpb and sternotomy (to include subjects who are undergoing first time or redo cardiac surgery) * abdominal aortic aneurysm repair * carotid endarterectomy * esophagectomy * cystectomy * nephrectomy * insulin dependent diabetes mellitis * anticipated administration of intraoperative steroids * major end organ dysfunction, defined as: * current intravenous inotropic agents * preoperative use of intra-aortic balloon pump (iabp), left ventricular assist device (lvad), or extracorporeal membrane oxygenation (ecmo) * renal * preoperative serum creatinine \> 2.0 mg/dl * hepatic * history of abnormal hepatic function in the past * hematologic * preoperative hematocrit (hct) \< 30% * platelet count \< 100,000/mm3 * history of bleeding or clotting disorder
long-term pacemaker arrhythmia analysis

Conditions: Atrial Fibrillation

Summary: investigators seek to observe the long term patterns of arrhythmias detected by permanent pacemakers.


Eligibility criteria:
inclusion criteria: * pre-existing dual chamber permanent pacemaker exclusion criteria: * nil
anterior cruciate ligament pain study

Conditions: Anterior Cruciate Ligament Reconstruction

Summary: the objective of this study is to compare the pain control benefit of two different types of nerve blocks in patients undergoing anterior cruciate ligament (acl) reconstruction.

this trial is a prospective, randomized, surgeon-blinded, two-armed trial to investigate the safety and efficacy of femoral nerve blocks versus adductor canal blocks for participants undergoing outpatient anterior cruciate ligament (acl) reconstruction surgery. the objective of this study is to compare the pain control benefit of two different types of nerve blocks. ropivacaine, which is fda-approved for use in both femoral nerve blocks as well as adductor canal blocks, will be utilized. the study will be comparing the efficacy between fda approved treatments.

Eligibility criteria:
inclusion criteria: * patients undergoing scheduled anterior cruciate ligament (acl) surgery at the emory orthopaedic and spine center * patients willing and able to provide written informed consent * parents willing and able to provide written informed consent for minors exclusion criteria: * patients who are pregnant or lactating * patients with liver dysfunction or renal failure * patients with a known allergy to ropivacaine * patients with a local infection * patients who take chronic pain medications * patients with an opioid tolerance * patients with known coagulopathy or bleeding risk. * patients who are getting neuraxial anesthesia for surgery
highly processed foods and vascular health

Conditions: Cardiovascular Diseases

Summary: age is the primary risk factor for cardiovascular disease (cvd) and age-related vascular dysfunction is considered the key process linking the two. middle age is a particularly vulnerable period when risk factors exceed diagnostic thresholds and clinical expression of cvd first becomes evident. ultra-processed foods (upf) comprise almost 60% of total energy in the standard american diet. the results of observational studies suggest that upf consumption increases cvd risk, independent of overall diet quality (i.e., saturated fat, sodium, sugar, and dietary fiber intake). the "industrialized microbiota" may link diet, particularly upf, to increased inflammation and cvd in middle-aged adults. high intake of upf increases the likelihood of an excess heart age \>10 years and doubles the risk of subclinical coronary atherosclerosis in middle-aged adults. however, the impact of reducing upf consumption on vascular function in middle-aged adults is unknown. the overall objective of this study is to establish proof-of-concept for an improvement in vascular function following reductions in upf consumption in mid-life adults, in order to conduct a larger, more comprehensive and mechanistic trial in the future. in addition, changes in gut microbial composition and function, intestinal inflammation and permeability, serum endotoxin concentrations, and inflammatory cytokines as potential mechanisms by which upf consumption influences vascular function will be investigated.


Eligibility criteria:
inclusion criteria: * weight stable for previous 6 months (\<2 kg change) * sedentary to recreationally active * no plans to gain/lose weight or change physical activity level * willing to pick up food daily and consume foods provided for an 8-week period * verbal and written informed consent * approval by medical director * usual upf intake +/-15% of us average of 60% total energy * estrogen or testosterone usage is acceptable, if on stable dose for \>6 months * lipid-lowering medication usage is acceptable, if on a stable dose for \>6 months exclusion criteria: * bmi \>35 kg/m2 * diabetes or diabetes medication * antibiotic, prebiotic or prebiotic use in prior 3 months * total cholesterol \>6.2 mmol/l; triglycerides \>4.5 mmol/l * blood pressure (bp) \> 159/99 mmhg (stable bp on antihypertensive medications is acceptable) * diagnosed inflammatory bowel disease * past or current heart diseases, stroke, respiratory disease, endocrine or metabolic disease, or hematological-oncological disease * vegetarian or vegan * pregnant or plans to become pregnant * food allergies or aversions * 3 or fewer stools per week or regular laxative use * lipid-lowering medication usage \<6 months
safety and efficacy of allo-605 an anti-bcma allogeneic car t cell therapy in patients with relapsed/refractory multiple myeloma

Conditions: Relapsed/Refractory Multiple Myeloma

Summary: the purpose of the allo-605-201 study is to assess the safety, efficacy, and cell kinetics of allo605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and allo-647.


Eligibility criteria:
inclusion criteria: * documented diagnosis of relapsed/refractory multiple myeloma (mm) * subjects must have measurable disease * subjects must have received ≥3 prior mm lines of therapy * eastern cooperative oncology group (ecog) performance status of 0 or 1 * adequate hematologic, renal, liver, pulmonary, and cardiac functions * life expectancy of at least 3 months without treatment exclusion criteria: * subjects with known active or history of central nervous system (cns) or leptomeningeal involvement of myeloma or plasma cell leukemia * current or history of thyroid disorder (including hyperthyroidism), except for subjects with hypothyroidism controlled on a stable dose of hormone replacement therapy * autologous stem cell transplantation within last 6 weeks prior to the start of lymphodepletion * any prior allogeneic hematopoietic stem cell transplantation * systemic anti-cancer therapy within 2 weeks prior to the start of lymphodepletion

Keywords: car t cell therapy allogeneic cell therapy cellular immuno-therapy allocar t allo-605 allo-647 multiple myeloma
treating primary progressive aphasia and apraxia of speech using non-invasive brain stimulation

Conditions: Primary Progressive Aphasia; Apraxia of Speech

Summary: the purpose of the study is to test whether low level electric stimulation, called transcranial direct current stimulation (tdcs), on the part of the brain (i.e., pre-supplementary motor area and left inferior frontal gyrus) thought to aid in memory will improve speech and language difficulties in patients with primary progressive aphasia (ppa) and progressive apraxia of speech (paos). the primary outcome measures are neuropsychological assessments of speech and language functions, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (eeg) measures.

this pilot study has one treatment arm with open-label treatment and will examine improvement of speech output, verbal fluency, and other cognitive deficits associated with primary progressive aphasia (ppa) and progressive apraxia of speech (paos), by utilizing 1 milliamp transcranial direct current stimulation (tdcs) active treatment applied to pre-supplementary motor area or left inferior frontal gyrus for 20 minutes over 10 sessions. there will be baseline testing, and follow up testing immediately after and 8 weeks after completion of treatment. all patients with a clinical diagnosis of ppa or paos will be assigned to either one of the two open-label arms to receive active tdcs. primary outcome speech and language measures, secondary neuropsychological and electroencephalography (eeg) measures, and pre-screening assessments for study medical history and contraindications for treatment will be collected prior to the treatment (i.e., baseline). primary outcome speech and language functions measures and secondary neuropsychological and electroencephalography (eeg) measures will be collected after treatment session 10 and following treatment competition (i.e., 8-week).

Eligibility criteria:
inclusion criteria: * 18 to 85 years of age * a formal diagnosis of primary progressive aphasia (nonfluent/agrammatic, semantic, logopenic variants or mixed) and/or progressive apraxia of speech * capable of understanding and signing an informed consent. medical information/history, as well as mental status exam and diagnosis provided by referring physician will determine whether or not a caregiver is required to be involved during this process. exclusion criteria: * has an implanted device, such as a pacemaker, metallic cranial implant, or a neurostimulator * skull defects * pregnant * a significant history of arrhythmia or epileptic seizures. * not a native english speaker * currently receiving speech-language intervention * unable to communicated verbally
visual dysfunction in mild traumatic brain injury (mtbi): a comparison group study

Conditions: Post-Traumatic Stress Disorder

Summary: in an on-going study of visual characteristics of personnel diagnosed with a mild traumatic brain injury (mtbi) related to their service in iraq and afghanistan we found a high rate of binocular vision problems (such as double/blurry vision, reading difficult, etc.). these individuals are also usually diagnosed with post traumatic stress disorder (ptsd). ptsd is known to cause some vision symptoms. we wish to conduct this study on individuals with ptsd (but not an mtbi) to see if they have symptoms similar to those in individuals who have mtbi. this will provide us with information useful in determining the specific cause of the visual symptoms in the mtbi population.

we will recruit 75 patients diagnosed with ptsd, but with no history of mild traumatic brain injury (mtbi), from the population of the vapahcs ptsd center and clinics. these volunteers will be scheduled for an eye screening developed for a concurrent project to assess visual dysfunction (accommodation/vergence insufficiency, pursuit/saccade deficits, etc.) in patients diagnosed with mtbi and seen at the palo alto polytrauma network site clinic. the mtbi patients have unexpectedly high rates of binocular dysfunction, although their visual acuities and visual fields are normal/near normal. the mtbi diagnosis is associated with a combat blast event in some 90% of cases. th majority of this population has also been diagnosed with ptsd. ptsd is known to cause some visual symptoms, thus it is necessary for us to determine if the visual dysfunctions in the mtbi are related to their ptsd diagnosis or not. the volunteer participants will be scheduled for an eye screening and consented prior to the screening. inclusion criteria include diagnosis of ptsd, aged 19 to 39, and willingness to participate. exclusion criteria is primarily history of tbi. the visual screen includes assessments of visual acuity, visual field, self-reported visual function (i.e., light sensitivity, eye fatigue, reading difficulty), and measures of accommodative function, vergence, pursuit and saccades. the data collected will be compared to the data from the ongoing study of visual dysfunction in patients diagnosed with mtbi.

Eligibility criteria:
inclusion criteria: * diagnosis of ptsd * no history of mtbi * between 19 and 39 years of age * a veteran exclusion criteria: * a history of mtbi * over the age of 39 * an unwillingness to participate
blood levels of sevoflurane and desflurane

Conditions: Anesthetics, Inhalation

Summary: 16 patients with american society of anesthesioiogy (asa) physical status i-iii will recruited to this study. patients will divided to the 2 groups. %1.5 sevoflurane will apply in group s and %6 desflurane will apply in group d. each groups will divide 2 subgroups. two lung ventilation will be performed to group sa and group da, one lung ventilation will be performed to group sb and group db. at the time point 40.minutes first blood sample will given from patients. blood sample will be taken at intervals of 10 minutes from groups of two lung ventilation. in groups of one lung ventilation, blood samples will be taken at the time interval of 10 minutes after one lung ventilation started. all blood samples will be assess in gas chromatography.

investigator aimed to assess blood level of sevoflurane and desflurane during two lung ventilation and one lung ventilation. the investigators will use gas chromatography for define drugs levels. 16 patients with asa i-iii patients who undergo thoracotomy and abdominal surgery will be recruited to this study. patients will divided in to the 2 groups. %1.5 sevoflurane will apply in group s and %6 desflurane will apply in group d during anesthesia maintenance. each groups will divide 2 subgroups which are one lung ventilation groups and two lung ventilation groups. two lung ventilation will be performed to group sa and group da, one lung ventilation will be performed to group sb and group db. sequential blood samples will be taken from both arterial and central venous canula at the same time point. first blood samples will be taken at 40. minutes of anesthesia. sequential samples will be taken at interval of 10 minutes during two lung ventilation. in one lung ventilation second blood samples will be taken at the 10. minutes of one lung ventilation. after than at the interval of 10 minutes, collection of blood samples both arterial and central venous will be continue. all collection will assess with gas chromatography.

Eligibility criteria:
inclusion criteria: asa i-ii patients * who undergo thoracotomy or abdominal surgery exclusion criteria: * asa iv and up patients * patients who taken inotropic agent

Keywords: blood sevoflurane concentration blood desflurane concentration one lung ventilation
trial of the presview implant for the improvement of near vision in presbyopic patients

Conditions: Presbyopia

Summary: study to determine the effectiveness of the presview scleral implant to improve near vision in patients who require reading glasses


Eligibility criteria:
inclusion criteria: * age 45 or older at commencement of study * best corrected distance visual acuity of .80 (20/25) or better * patients must be alert, mentally competent, and able to comply with clinical study requirements exclusion criteria: * any previous eye surgeries including cataract, lasik (laser in situ keratomileusis), or eye muscle surgery * any chronic systemic diseases such as diabetes, heart disease, lupus, etc. * any eye diseases such as eye inflammation, infection, cataract, or retinal diseases

Keywords: presbyopia reading glasses near vision
the study of heart failure with human umbilical cord mesenchymal stem cells (19#isclife®-hf)

Conditions: Heart Failure

Summary: the purposes of the study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (huc-msc) in treating heart failure patients

this is a randomized, paralleled study. patients will be divided into two groups of treatment and control. all of them will receive conventional treatment based on specific condition, including digitalis, milrinone, furosemide, beta-blocker blues, angiotensin-converting enzyme inhibitors (acei), angiotension receptor blocker (arb), and antiplatelet aggregation etc. treatment group patients will receive huc-msc. follow-up visit will occur on 3 months, 6 months, and 12 months after the cell transfusion. vital signs, blood routine test, urine routine test, liver function examination, etc, will be placed to evaluate the safety of huc-msc treatment. and the change of symptoms to evaluate the efficacy.

Eligibility criteria:
inclusion criteria: * volunteer to participate in clinical trial, and sign informed consent form * with cardiac failure symptoms, including oppression in chest, breathe hard, lower limb edema. and new york heart association class as two to four * heart color ultrasound indicate left ventricular ejection fraction (lvef) \< 40% * content of serum nt-probnp \> 450pg/ml exclusion criteria: * with severe drug allergy history or allergic constitution * patients were severe infected * with malignant tumor or with high tumor marker * with severe cardiorespiratory dysfunction, hematological system disease * with severe mental disorder, cognitive impairment * with persistent atrial fibrillation, valvular heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy or restrictive cardiomyopathy patients * end-stage renal insufficiency, pregnancy, or breast feeding women * bleeding tendency, active gastrointestinal ulcer * recent have major surgery, stroke, cancer, hepatic function insufficiency or other life-threatening condition. * under other therapy that possibly influence msc security or efficacy * donor: hiv, active hepatitis b/c infection, syphilitic antibody positive * participant/donor: alcoholism, drug addicted, mental disease

Keywords: heart failure human umbilical cord mesenchymal stem cells
study of mind-body skills groups for adolescents with depression in primary care

Conditions: Depression; Depressive Disorder

Summary: the center for mind -body medicine has developed a mind-body skills group program that incorporates meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement. these mind-body skills are designed to increase self-awareness and self-regulation. this program has been shown to significantly improve depression symptoms in children and adolescents with posttraumatic stress disorder in gaza, but it has not yet been tested in a us adolescent population. the purpose of this study is to determine the feasibility of using mind-body skills groups to reduce depression in adolescents and to investigate the effects of the program on factors such as self-efficacy, mindfulness and rumination which are likely to mediate improvement.


Eligibility criteria:
inclusion criteria: * eskenazi primary care patients at time of screening * 13-17 years old * diagnosis of depression confirmed by mini international neuropsychiatric interview (mini) kid screen (with adolescent) * english speaking * willingness to attend mind body skills group for duration of the intervention (10 sessions over approximately 10 weeks) exclusion criteria: * history of bipolar disorder or psychosis * acute and immediate risk of suicide, determined by clinical assessment * lack of capacity to assent (adolescent) or lack of capacity to consent (parent/guardian) * previous participation by the adolescent in the eskenazi mind body group intervention

Keywords: depression adolescent mind-body-skills group therapy primary care